Drug Profile
LTX 109
Alternative Names: LTX-109; LytixarLatest Information Update: 26 Dec 2022
Price :
$50
*
At a glance
- Originator Lytix Biopharma; Pharma Holdings AS
- Class Antibacterials; Oligopeptides; Small molecules
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II COVID 2019 infections
- Phase I/II Hidradenitis suppurativa; Methicillin-resistant Staphylococcus aureus infections
- Discontinued Diabetic foot ulcer; Impetigo; Skin and soft tissue infections
Most Recent Events
- 18 Oct 2022 Pharma Holdings completes a phase IIa trial in Healthy volunteers in Sweden (Intranasal, Gel) (EudraCT2022-001938-11)
- 22 Aug 2022 Pharma Holdings completes a phase-II trial in COVID-2019 infections (In adults, In the elderly) in Sweden (Intranasal) (EudraCT2021-000455-39) (NCT04854928)
- 18 Aug 2022 Pharma Holdings initiates enrollment in a phase IIa trial in Healthy volunteers in Sweden (Intranasal, Gel) (EudraCT2022-001938-11)